These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

429 related items for PubMed ID: 20692233

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Plasma globotriaosylsphingosine as a biomarker of Fabry disease.
    Togawa T, Kodama T, Suzuki T, Sugawara K, Tsukimura T, Ohashi T, Ishige N, Suzuki K, Kitagawa T, Sakuraba H.
    Mol Genet Metab; 2010 Jul; 100(3):257-61. PubMed ID: 20409739
    [Abstract] [Full Text] [Related]

  • 3. Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy.
    Sakuraba H, Togawa T, Tsukimura T, Kato H.
    Clin Exp Nephrol; 2018 Aug; 22(4):843-849. PubMed ID: 29288396
    [Abstract] [Full Text] [Related]

  • 4. Multiplex tandem mass spectrometry analysis of novel plasma lyso-Gb₃-related analogues in Fabry disease.
    Boutin M, Auray-Blais C.
    Anal Chem; 2014 Apr 01; 86(7):3476-83. PubMed ID: 24634980
    [Abstract] [Full Text] [Related]

  • 5. Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease.
    Sueoka H, Aoki M, Tsukimura T, Togawa T, Sakuraba H.
    PLoS One; 2015 Apr 01; 10(12):e0144958. PubMed ID: 26661087
    [Abstract] [Full Text] [Related]

  • 6. Profiles of Globotriaosylsphingosine Analogs and Globotriaosylceramide Isoforms Accumulated in Body Fluids from Various Phenotypic Fabry Patients.
    Shiga T, Tsukimura T, Kubota T, Togawa T, Sakuraba H.
    Intern Med; 2024 Jun 01; 63(11):1531-1537. PubMed ID: 37866916
    [Abstract] [Full Text] [Related]

  • 7. Effects of switching from agalsidase-α to agalsidase-β on biomarkers, renal and cardiac parameters, and disease severity in fabry disease forming neutralizing antidrug antibodies: a case report.
    Shima H, Tsukimura T, Shiga T, Togawa T, Sakuraba H, Doi T, Ikeda Y, Okamoto T, Yoshikawa Y, Kimura T, Iwase T, Inoue T, Tashiro M, Okada K, Minakuchi J.
    CEN Case Rep; 2024 Aug 01; 13(4):290-296. PubMed ID: 38135868
    [Abstract] [Full Text] [Related]

  • 8. Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease.
    Niemann M, Rolfs A, Störk S, Bijnens B, Breunig F, Beer M, Ertl G, Wanner C, Weidemann F.
    Circ Cardiovasc Genet; 2014 Feb 01; 7(1):8-16. PubMed ID: 24395922
    [Abstract] [Full Text] [Related]

  • 9. A simple method for quantification of plasma globotriaosylsphingosine: Utility for Fabry disease.
    Talbot A, Nicholls K, Fletcher JM, Fuller M.
    Mol Genet Metab; 2017 Sep 01; 122(1-2):121-125. PubMed ID: 28847675
    [Abstract] [Full Text] [Related]

  • 10. Globotriaosylsphingosine (lyso-Gb3) and analogues in plasma and urine of patients with Fabry disease and correlations with long-term treatment and genotypes in a nationwide female Danish cohort.
    Effraimidis G, Feldt-Rasmussen U, Rasmussen ÅK, Lavoie P, Abaoui M, Boutin M, Auray-Blais C.
    J Med Genet; 2021 Oct 01; 58(10):692-700. PubMed ID: 32963035
    [Abstract] [Full Text] [Related]

  • 11. Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy.
    Quinta R, Rodrigues D, Assunção M, Macedo MF, Azevedo O, Cunha D, Oliveira P, Sá Miranda MC.
    Gene; 2014 Feb 15; 536(1):97-104. PubMed ID: 24334116
    [Abstract] [Full Text] [Related]

  • 12. How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?
    Auray-Blais C, Ntwari A, Clarke JT, Warnock DG, Oliveira JP, Young SP, Millington DS, Bichet DG, Sirrs S, West ML, Casey R, Hwu WL, Keutzer JM, Zhang XK, Gagnon R.
    Clin Chim Acta; 2010 Dec 14; 411(23-24):1906-14. PubMed ID: 20716442
    [Abstract] [Full Text] [Related]

  • 13. A comprehensive testing algorithm for the diagnosis of Fabry disease in males and females.
    Stiles AR, Zhang H, Dai J, McCaw P, Beasley J, Rehder C, Koeberl DD, McDonald M, Bali DS, Young SP.
    Mol Genet Metab; 2020 Jul 14; 130(3):209-214. PubMed ID: 32418857
    [Abstract] [Full Text] [Related]

  • 14. Plasma globotriaosylsphingosine (lysoGb3) could be a biomarker for Fabry disease with a Chinese hotspot late-onset mutation (IVS4+919G>A).
    Liao HC, Huang YH, Chen YJ, Kao SM, Lin HY, Huang CK, Liu HC, Hsu TR, Lin SP, Yang CF, Fann CS, Chiu PC, Hsieh KS, Fu YC, Ke YY, Lin CY, Tsai FJ, Wang CH, Chao MC, Yu WC, Chiang CC, Niu DM.
    Clin Chim Acta; 2013 Nov 15; 426():114-20. PubMed ID: 24055776
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
    Tsuboi K, Yamamoto H.
    BMC Pharmacol Toxicol; 2017 Jun 07; 18(1):43. PubMed ID: 28592315
    [Abstract] [Full Text] [Related]

  • 16. Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients.
    Young-Gqamana B, Brignol N, Chang HH, Khanna R, Soska R, Fuller M, Sitaraman SA, Germain DP, Giugliani R, Hughes DA, Mehta A, Nicholls K, Boudes P, Lockhart DJ, Valenzano KJ, Benjamin ER.
    PLoS One; 2013 Jun 07; 8(3):e57631. PubMed ID: 23472096
    [Abstract] [Full Text] [Related]

  • 17. Differences in cleavage of globotriaosylceramide and its derivatives accumulated in organs of young Fabry mice following enzyme replacement therapy.
    Kodama T, Tsukimura T, Kawashima I, Sato A, Sakuraba H, Togawa T.
    Mol Genet Metab; 2017 Jun 07; 120(1-2):116-120. PubMed ID: 27756537
    [Abstract] [Full Text] [Related]

  • 18. Diurnal Variation of Urinary Fabry Disease Biomarkers during Enzyme Replacement Therapy Cycles.
    Boutin M, Lavoie P, Menkovic I, Toupin A, Abaoui M, Elidrissi-Elawad M, Arthus MF, Fortier C, Ménard C, Maranda B, Bichet DG, Auray-Blais C.
    Int J Mol Sci; 2020 Aug 25; 21(17):. PubMed ID: 32854306
    [Abstract] [Full Text] [Related]

  • 19. Nano-LC-MS/MS for Quantification of Lyso-Gb3 and Its Analogues Reveals a Useful Biomarker for Fabry Disease.
    Sueoka H, Ichihara J, Tsukimura T, Togawa T, Sakuraba H.
    PLoS One; 2015 Aug 25; 10(5):e0127048. PubMed ID: 25965380
    [Abstract] [Full Text] [Related]

  • 20. Investigation of bone mineral density and the changes by enzyme replacement therapy in patients with Fabry disease.
    Nose Y, Fujii H, Goto S, Kono K, Okamoto H, Watanabe K, Nishi S.
    Mol Genet Metab; 2023 Aug 25; 139(4):107634. PubMed ID: 37406430
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.